Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07213349 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Daridorexant for Alzheimer Disease Prevention

Study acronym: PAD-DORA
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 7, 2025 to Oct 14, 2025
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer's disease dementia, regardless of whether or not they experience sleep problems.
Trial Details
NCT Number NCT07213349
Lead Sponsor Douglas Mental Health University Institute
Collaborators: Weston Family Foundation
Conditions
(from sponsor)		 Alzheimer Disease (AD)
Related terms Alzheimer Disease, Cognitive Dysfunction, Pick Disease of the Brain
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov